Background-Inhibition of leukocyte adhesion can reduce myocardial infarct size in animals. This study was designed to define the safety and efficacy of a recombinant, humanized, monoclonal antibody to the CD18 subunit of the ␤2 integrin adhesion receptors (rhuMAb CD18), in reducing infarct size in patients treated with a thrombolytic agent.
Ն1 mm in Ն2 contiguous leads on a 12-lead ECG) who were eligible for treatment with front-loaded recombinant tissue plasminogen activator (rtPA) were included. Exclusion criteria were symptom duration Ͼ12 hours; oral temperature Ն101.5°F; treatment with any thrombolytic agent within 4 days; previous coronary surgery; cardiogenic shock (systolic blood pressure Ͻ90 mm Hg with intravenous vasopressors or Ͻ80 mm Hg without intravenous vasopressors); inability to undergo cardiac catheterization, including known contrast dye allergy; major surgery, biopsy of a parenchymal organ, or significant trauma, within 3 months; prolonged cardiopulmonary resuscitation (Ͼ2 minutes) within 2 weeks; recent noncompressible vascular puncture; left bundle branch block; systolic blood pressure Ͼ180 mm Hg and/or diastolic blood pressure Ͼ110 mm Hg on Ն1 reliable measurement during admission; bleeding disorder within the past 6 months; any history of stroke, transient ischemic attack, or central nervous system structural damage; therapeutic oral anticoagulation (defined as an international normalized ratio [INR] Ն1.4); pregnancy; parturition within 30 days; childbearing potential not using adequate birth control methods; active infection or current use of oral antibiotics; other serious illness (eg, active cancer, HIV infection); other illnesses or therapies known to impair the immune system, such as nontopical corticosteroids; inability to follow the protocol and comply with follow-up requirements; current participation in another experimental drug or device treatment protocol; prior administration of rhuMAb CD18; or any other condition that the Investigator believed would pose a significant hazard to the subject if the investigational therapy were administered.
Treatment Regimen
Subjects were randomized by a dynamic Interactive Voice Response System, in a 1:1:1 ratio, to 0.5 mg/kg or 2.0 mg/kg rhuMAb CD18 or to matching placebo administered before commencing rtPA or as soon as possible thereafter plus aspirin (325 mg) and intravenous heparin (4000 to 5000 U bolus, followed by 800 to 1000 U/h initially). The target activated partial thromboplastin time for heparinization was 55 to 80 seconds. Coronary angiography was performed 90 minutes after rtPA administration. After obtaining a view of the infarct-related artery, intervention with balloon angioplasty and/or coronary stent placement was performed at the investigator's discretion after 90 minutes, unless clinically mandated earlier. The duration of heparinization and the use of other medications, such as glycoprotein IIb/IIIa inhibitors, were at the attending physician's discretion.
End Points
The primary end point was the corrected TIMI frame count 9 (CTFC) at 90 minutes. Secondary efficacy end points were percent TIMI grade 3 flow at 90-minute angiography, myocardial infarct size assessed by SPECT at Ն120 hours, and ECG ST-segment elevation resolution at 3 hours. In addition, TIMI myocardial perfusion grade 10 during angiography and ECG ST-segment resolution immediately before angiography were assessed. Prospective calculations for selection of sample size were based on 80% power for observing a 15% difference in the proportion of subjects with TIMI 3 flow, ie, 55% (placebo) versus 70% (rhuMAb CD18).
Coronary Blood Flow
Angiograms were performed conventionally, and end points were determined by the blinded investigator (C.M.G.), who recorded CTFC, TIMI flow grade, 11 and perfusion grade within a window of 80 to 105 minutes after the administration of rtPA (85% of patients). In a few cases, missing CTFC data were imput as the median CTFC of TIMI flow grade. End point values for completely missing data (death or cardiogenic shock before 105 minutes) were imputed as 100 for CTFC and 0 for TIMI flow grade.
Infarct Size
Infarct size was assessed by 99m Tc-sestamibi SPECT imaging at rest or Ն120 hours after drug administration. The proportion of the left ventricle perfusion deficit was estimated conventionally. 12 Missing data (missing or Յ120 hours) were imputed by linear regression from creatine kinase-MB 72-hour time-activity curves. 13, 14 If creatine kinase-MB data were incomplete (early death), the 90th percentile of SPECT-determined infarct size was imputed.
ECG ST Segment Elevation Resolution
Standard 12-lead ECGs were obtained at baseline and at 90 and 180 minutes after rtPA. When possible, the 90-minute ECG was obtained before angiography. ECGs were analyzed by a blinded core laboratory that characterized ST-segment elevation 20 ms after the J point. The percentage resolution from baseline in the sum of ST elevation was categorized as follows: complete (Ն70%), partial (30% to Ͻ70%), or absent (0 to Ͻ30%) 15 in 60 to 120 minute (90-minute) and 120 to 240 minute (3-hour) windows.
Statistical Analysis
Continuous variable results are expressed as meanϮSD, medians, and percentiles. Two comparisons were prospectively defined for efficacy end points: placebo versus low dose and placebo versus high 
Results
A total of 394 subjects were randomized and treated with rhuMAb CD18 or placebo. An additional 22 subjects were withdrawn before study drug administration. Patient characteristics are shown in Table 1 .
There were no differences between placebo and active rhuMAb CD18 groups in any efficacy end point ( Figure 1 and Table 2 ). The incidence of TIMI grade 3 flow in the placebo group was unexpectedly high (66%). Neither the proportion of subjects with TIMI myocardial perfusion grade 2 or 3 or infarct size or ECG ST-segment resolution end points exhibited a treatment effect (Table 3 ). No treatment effect was observed in the following subgroups (data not shown): treatment Յ3 hours, men versus women, or use of a glycoprotein IIb/IIIa inhibitor in the first 2 days.
There was no excess of any specific adverse event in the rhuMAb CD18 groups. However, when adverse event terms were grouped as those consistent with a "likely bacterial infection" (defined as sepsis, nonaspiration pneumonia, urinary tract infection, pyuria, abscess, furunculosis, nonviral infection, and abnormal healing) a trend toward a conse-quence of treatment was noted (Table 4 ; Pϭ0.33 for trend). One self-limited, severe, febrile reaction was reported 30 minutes after the administration of a 2.0 mg/kg dose of rhuMAb CD18. There was no effect of rhuMAb CD18 on "serious and life-threatening" bleeding events, although the incidence of overall bleeding events was slightly higher in the rhuMAb CD18 groups (Table 4 ). White cell count increased from a baseline of Ϸ11 000 cells/mL in all groups to a peak of Ϸ16 000 to 17 000 at 24 hours in both rhuMAb CD18 groups, which returned toward normal more slowly in the highest dose group (Figure 2) . No treatment effects were seen with respect to hemoglobin, platelet count, white cell differential count, fibrinogen, d-dimer, liver function, creatinine, or ferritin. No antibody formation to the active binding sites of rhuMAb CD18 was observed.
The mortality in the study population as a whole was 4.8% at day 30, and 5.1% at day 90. There were no significant differences between groups in the incidence of recurrent AMI, heart failure, or a composite end point (death, recurrent AMI, and serious/severe heart failure) at day 30 (Table 4 ).
Discussion
Our results demonstrated no effects of rhuMAb CD18 on multiple cardiac end points. The failure of anti-CD18 therapy in human subjects, despite positive findings in most experimental animal studies, 1,2,4,16 was surprising. However, results in canine models were varied, with no effect on infarct size, despite an apparent increase in post-reperfusion blood flow in one study 6 and efficacy in another with 2 of 3 anti-CD18 antibodies tested. In a third study, efficacy was not seen when myocardial ischemia was severe. 17 One possible explanation for the failure of anti-CD18 therapy in humans is that the duration of ischemia is so long that endothelial cell barrier function fails. If so, blocking the Mac-1-intracellular adhesion molecule interaction would not prevent neutrophils from migrating into the subendothelial tissues and contributing to tissue damage. The median time of presentation (2.7 hours) was longer than the Յ90 minutes of experimental ischemia studied in animals. In rabbits with myocardial infarction, anti-CD18 therapy was effective after coronary occlusion lasting 30 but not 45 minutes. 18 By contrast, in dogs with neutrophil depletion, myocardial necrosis was reduced with ischemia of either 90 or 240 minutes. 5 Sharar et al 3 found, using a rabbit ear preparation and 6 hours of occlusion, that administration of anti-CD18 therapy immediately on reperfusion was as effective as that initiated 1 hour but not 4 hours later. No effect was observed when the antibody was administered after 12 hours.
At least 2 in vitro studies have reported CD18-independent migration across human endothelial cell layers in response to selected stimuli. 19, 20 The mechanism of CD18-independent migration is not understood. It may be organ-dependent, with blocking antibodies consistently showing complete inhibition of neutrophil migration into skin but not into lung or liver. 21 Although other families of adhesion receptors are well known, it is the ␤2 family, all of which contain CD18 subunits, that is thought to enable firm neutrophil attachment as a prelude to migration. 22 Leukocytes and/or acute inflammation may not be critical to the amount of myocardial damage after coronary occlusion in humans. This possibility is consistent with the failure of large doses of methylprednisolone to improve AMI outcome. 23 Medications with possible activity against leukocyte adhesion used in this study included unfractionated heparin and abciximab. Either could have influenced the effects of rhuMAb CD18. 24 -26 Doses of unfractionated heparin low enough not to affect the activated partial thromboplastin time bind to Mac-1 and interfere with n-formyl-methionineleucine-phenylalanine (fMLP)-induced leukocyte-endothelial adhesion in rats. 27 The time course of the leukocytosis after anti-CD18 therapy is consistent with the prevention of margination of leukocytes, and yet this anti-adhesion phenomenon has not been reported with either heparin or abciximab. Mac-1 (CD18/11b, occurring mainly on neutrophils and monocytes) is also a receptor for C3bi and fibrinogen. Interference with its functions is seen in vivo and in vitro at clinically relevant concentrations of heparin. 24 Thus, heparin may have interfered with anti-CD18 effects in this study.
Despite an unexpectedly high proportion of subjects with TIMI grade 3 flow at 90 minutes after rtPA (66%) in the placebo group, the study had adequate power to detect treatment effects. The power of this study to demonstrate the expected 15% absolute increase in TIMI grade 3 flow rate (from the observed rate of 66% to 81%) was Ϸ70%.
The protocol design was sufficiently sensitive to detect clinically relevant effects of anti-CD18 treatment in view of the multiple cardiac end points assessed. Coronary flow and 90-minute ECG end points were obtained before mechanical intervention to avoid confounding effects of the intervention itself. Blinded core reference laboratories were used to assess efficacy end points independently. The levels of missing data were acceptable, and the findings were robust in regard to analysis methods. The doses studied resulted in the expected plasma concentrations and were sufficient to fully saturate CD18 receptors within the first few hours. Biological activity was evident, as judged from the 2-fold rise in mean peripheral white cell counts in both active treatment groups. Thus, it seems that dosage was adequate.
Our results indicate that rhuMAb CD18 was well tolerated but lacked any beneficial cardiac effects in patients with ST-segment elevation AMI. All serious adverse events, † n 3 0 3 0 2 4
All infections, † % 3 7 4 0 3 4
Likely bacterial infection, † % 1 1 1 3 1 5
All bleeding events, † % 5 9 6 4 6 7
Serious and life-threatening bleeding, ‡ % 6 7 5
Recurrent myocardial infarction, ‡ % 4 2 3
Coronary bypass surgery, ‡ % 1 3 9 1 2
Serious/severe heart failure, † § % 7 8 1 2
Composite end point of death, recurrent AMI, or serious/severe heart failure, † % 12 11 15 *No statistically significant comparisons. †Up to and including day 30. ‡Up to the first hospital discharge. §Defined as reports of heart failure of Killip class III or IV, readmission for heart failure, or serious or severe adverse events of heart failure.
